Scholarlink

<p>Osteoporosis is driven in part by excessive osteoclast-mediated bone resorption, yet osteoblast-derived extracellular cues that restrain osteoclast bioenergetics remain incompletely defined. Here we identify osteomodulin (OMD), a matrix-associated osteoblast-derived protein that is reduced in the bone tissue and serum of postmenopausal patients with osteoporosis. Inducible global or osteoblast-specific <i>Omd</i> deletion exacerbates bone loss and increases osteoclast activity, whereas osteoclast precursor-specific deletion produces no overt skeletal phenotype. Mechanistically, OMD engages integrin β8 on osteoclast precursors, suppresses RhoA activity and enhances YAP phosphorylation, thereby reducing YAP/TEAD occupancy at the ribonucleotide reductase M2 (RRM2) promoter and repressing <i>Rrm2</i> transcription. Consistent with RRM2’s role in maintaining the dNTP pools required for mitochondrial DNA replication, OMD decreases mtDNA copy number and the abundance of electron transport chain proteins, leading to reduced mitochondrial respiration and ATP production, with only limited glycolytic compensation. Finally, recombinant OMD supplementation or pharmacologic RRM2 inhibition mitigates ovariectomy and lipopolysaccharide-induced bone loss. Together, our findings identify an OMD-integrin β8-RhoA-YAP/TEAD-RRM2 axis that links extracellular matrix signaling to mitochondrial respiration and mitochondrial ATP production during osteoclastogenesis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Osteoblast-derived osteomodulin restrains osteoclastogenesis via ITGB8/RRM2-mediated reduction of mitochondrial respiration and mitochondrial ATP production

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月12日

查看全文
  • Xiaowen Jiang,
  • Han Chen,
  • Weiduo Hou,
  • Chengxin Dai,
  • Ruijie Zhang,
  • Erman Chen,
  • Jingjing Zhang,
  • Wanyi Wu,
  • Jianbin Xu,
  • Mo Chen,
  • Liang Liu,
  • Xun Tan,
  • Xiaoxiao Ji,
  • Xiaoyong Wu,
  • Kanbin Wang,
  • Chaorong Yu,
  • Xiaohua Yu,
  • Weixu Li,
  • Wei Zhang

摘要

Osteoporosis is driven in part by excessive osteoclast-mediated bone resorption, yet osteoblast-derived extracellular cues that restrain osteoclast bioenergetics remain incompletely defined. Here we identify osteomodulin (OMD), a matrix-associated osteoblast-derived protein that is reduced in the bone tissue and serum of postmenopausal patients with osteoporosis. Inducible global or osteoblast-specific Omd deletion exacerbates bone loss and increases osteoclast activity, whereas osteoclast precursor-specific deletion produces no overt skeletal phenotype. Mechanistically, OMD engages integrin β8 on osteoclast precursors, suppresses RhoA activity and enhances YAP phosphorylation, thereby reducing YAP/TEAD occupancy at the ribonucleotide reductase M2 (RRM2) promoter and repressing Rrm2 transcription. Consistent with RRM2’s role in maintaining the dNTP pools required for mitochondrial DNA replication, OMD decreases mtDNA copy number and the abundance of electron transport chain proteins, leading to reduced mitochondrial respiration and ATP production, with only limited glycolytic compensation. Finally, recombinant OMD supplementation or pharmacologic RRM2 inhibition mitigates ovariectomy and lipopolysaccharide-induced bone loss. Together, our findings identify an OMD-integrin β8-RhoA-YAP/TEAD-RRM2 axis that links extracellular matrix signaling to mitochondrial respiration and mitochondrial ATP production during osteoclastogenesis.